9,11-linoleic acid has been researched along with risperidone in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cain, R; Clark, AJ; Dilly, SJ; Fishwick, CWG; Marsh, A; Mitchell, DA; Taylor, PC | 1 |
1 other study(ies) available for 9,11-linoleic acid and risperidone
| Article | Year |
|---|---|
A chemical genomics approach to drug reprofiling in oncology: Antipsychotic drug risperidone as a potential adenocarcinoma treatment.
Topics: 17-Hydroxysteroid Dehydrogenases; 3-Hydroxyacyl CoA Dehydrogenases; Adenocarcinoma; Animals; Antineoplastic Agents; Antipsychotic Agents; Bacteriophage T7; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drosophila melanogaster; Drug Compounding; Drug Repositioning; Enzyme Inhibitors; Gene Library; Genomics; Humans; Linoleic Acids, Conjugated; Male; Mice, Nude; Molecular Docking Simulation; Molecular Targeted Therapy; Prostatic Neoplasms; Protein Conformation; Risperidone; Structure-Activity Relationship; Time Factors; Tumor Burden; Xenograft Model Antitumor Assays | 2017 |